Tourmaline Bio Receivables 2020-2025 | TRML

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Tourmaline Bio receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Tourmaline Bio receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$71.7B
Zoetis (ZTS)	$69.5B
Daiichi Sankyo, - (DSNKY)	$49.8B
Takeda Pharmaceutical (TAK)	$49.3B
BeOne Medicines - (ONC)	$33.9B
Sandoz Group AG (SDZNY)	$26.7B
Summit Therapeutics (SMMT)	$19.2B
Merck (MKKGY)	$16.8B
Shionogi (SGIOY)	$15.2B
United Therapeutics (UTHR)	$13.8B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$11.2B
IPSEN (IPSEY)	$11.2B
Eisai (ESAIY)	$9.3B
Madrigal Pharmaceuticals (MDGL)	$8.7B
Corcept Therapeutics (CORT)	$7.4B
Grifols, S.A (GRFS)	$7B
Stevanato Group S.p.A (STVN)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.4B
Ono Pharmaceutical (OPHLF)	$5.4B
Soleno Therapeutics (SLNO)	$3.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.7B
NewAmsterdam Pharma (NAMS)	$2.7B
Hypermarcas (HYPMY)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B
Endo (NDOI)	$1.8B